Oncternal Therapeutics Inc Stock Price, News & Analysis

Oncternal Therapeutics, Inc. (Nasdaq: ONCT) is hosting a Virtual Fireside Chat on April 18, 2023, at 1:30 PM EDT, focused on ROR1 CAR-T Cell Therapy for hematological malignancies and solid tumors. Moderated by Oppenheimer's Hartaj Singh, the discussion features key opinion leaders, including Dr. Michael Wang and Dr. Angela Shen, alongside Oncternal's CEO, Dr. James Breitmeyer. This event will highlight Oncternal's investigational CAR-T therapy, ONCT-808, which targets ROR1 and demonstrates preclinical success against several cancers. The company is advancing its development pipeline for treatments addressing critical unmet medical needs in oncology, particularly in aggressive B-cell lymphoma and prostate cancer.

Oncternal Therapeutics announced the closure of its zilovertamab Phase 3 study (ZILO-301) and Phase 1/2 study (CIRM-0001) due to the evolving market for BTK inhibitors. This strategic shift aims to extend the company’s cash runway into 2025, supporting further clinical development of ONCT-808 and ONCT-534. ONCT-808, targeting aggressive lymphomas, and ONCT-534, a novel AR inhibitor for mCRPC, are set to yield initial clinical data by late 2023 and mid-2024, respectively. The company's cash and equivalents are reported at $54.3 million, supporting operations through 2025. A webcast with management is scheduled for today at 5:00 PM ET.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announced the approval of an inducement award to new employee Erik S. Nelson as Head of IT. The award includes an option to purchase 64,900 shares of common stock, vesting over four years. This decision aligns with Oncternal's 2021 Employment Inducement Incentive Award Plan, aimed at attracting talent. The option price will match the stock's closing price on the grant date, April 3, 2023. The plan has been approved by independent directors per Nasdaq rules. Oncternal focuses on innovative oncology therapies targeting critical unmet medical needs in cancer treatment.

Oncternal Therapeutics (ONCT) announced significant advancements in its oncology programs, including promising interim results from a Phase 1/2 study of zilovertamab combined with ibrutinib for MCL and CLL patients, achieving an objective response rate of 89%. The company also initiated the global Phase 3 ZILO-301 study for zilovertamab and launched the Phase 1/2 study for ONCT-808, targeting ROR1-expressing malignancies. Positive FDA feedback on the dual-action androgen receptor inhibitor ONCT-534 supports an IND filing. With $63.7 million in cash, Oncternal expects to fund operations into Q1 2024.

Oncternal Therapeutics (Nasdaq: ONCT) will announce its fourth quarter and full year 2022 financial results on March 9, 2023, after U.S. markets close. A webcast for stakeholders will be hosted at 2:00 p.m. PT (5:00 p.m. ET) to discuss these results alongside a comprehensive business update. Oncternal focuses on developing novel therapies for oncology treatments, particularly in hematological malignancies and prostate cancer. The company's lead program, zilovertamab, is currently undergoing global Phase 3 trials in combination with ibrutinib for mantle cell lymphoma treatment.